Hyperion Therapeutics (NASDAQ:HPTX) shares are surging today following news that its drug RAVICTI was approved by the Food and Drug Administration for the treatment of a rare disease called urea cycle disorder. While RAVICTI isn't the first drug to treat the disease, its convenience is head and shoulders above the existing option. Follow along in the video below as health care bureau chief Brenton Flynn discusses the news and what's next for Hyperion now that RAVICTI is approved.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Horizon Pharma Plc Is Soaring Today
Horizon Pharma PLC is acquiring Hyperion Therapeutics, Inc. in a deal worth $1.1 billion.
This Week in Biotech: 2 FDA Approvals and 3 Clinically Impressive Studies
Two biopharma stocks bask in an FDA approval while three others head higher following positive clinical data -- including a triple-digit percent gainer!
Why Hyperion Therapeutics Inc. Shares Popped
Shares of Hyperion jumped after publishing successful midstage results for a key drug in the March issue of Hepatology. Should investors welcome this news with open arms or be cautious moving forward?